Cardax Inc. (CDXI) 0.3200 $CDXI
SeeThruEquity Initiates Research Coverage on Cardax, Inc. with a Target Price of $1.00
ACCESSWIRE - Mon Oct 06, 8:06AM CDT
New York, NY / ACCESSWIRE / October 6, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Cardax, Inc. (OTCQB: CDXI), Cardax is a development stage, life sciences company focused on introducing nutraceutical and pharmaceutical products aimed at reducing inflammation and oxidative stress.
Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors
Business Wire - Tue Jun 17, 7:01AM CDT
Cardax, Inc. ("Cardax"
(OTCQB:CDXI) announced today the appointment of George W. Bickerstaff, former CFO of Novartis Pharma AG (NYSE:NVS), Tamar D. Howson, former senior business development executive at Bristol-Myers Squibb (NYSE:BMY) and SmithKline Beecham, and Terence A. Kelly, Ph.D., former senior Boehringer Ingelheim anti-inflammatory R&D executive and current CEO of CoMentis, as independent members of its Board of Directors. They will join current Executive Chairman Nicholas Mitsakos, independent director Frank Herringer, and Cardax CEO David G. Watumull on the Cardax Board.
OXGN: 1.61 (+0.01), ACT: 285.37 (+3.71), LXRX: 0.89 (unch), ONVO: 6.34 (+0.07), IDIX: 24.50 (+0.05), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17)
SeeThruEquity Initiates Research Coverage on Cardax, Inc. with a Target Price of $1.00
ACCESSWIRE - Mon Oct 06, 8:06AM CDT
New York, NY / ACCESSWIRE / October 6, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Cardax, Inc. (OTCQB: CDXI), Cardax is a development stage, life sciences company focused on introducing nutraceutical and pharmaceutical products aimed at reducing inflammation and oxidative stress.
Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors
Business Wire - Tue Jun 17, 7:01AM CDT
Cardax, Inc. ("Cardax"
(OTCQB:CDXI) announced today the appointment of George W. Bickerstaff, former CFO of Novartis Pharma AG (NYSE:NVS), Tamar D. Howson, former senior business development executive at Bristol-Myers Squibb (NYSE:BMY) and SmithKline Beecham, and Terence A. Kelly, Ph.D., former senior Boehringer Ingelheim anti-inflammatory R&D executive and current CEO of CoMentis, as independent members of its Board of Directors. They will join current Executive Chairman Nicholas Mitsakos, independent director Frank Herringer, and Cardax CEO David G. Watumull on the Cardax Board. OXGN: 1.61 (+0.01), ACT: 285.37 (+3.71), LXRX: 0.89 (unch), ONVO: 6.34 (+0.07), IDIX: 24.50 (+0.05), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17)
